Entera Bio Ltd ENTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENTX is a good fit for your portfolio.
News
-
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
-
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
-
Thinking about buying stock in Entera Bio, Ocugen, Mind Medicine, MicroAlgo, or Flora Growth?
-
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
-
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
-
Thinking about buying stock in Mirum Pharmaceuticals, Entera Bio, Andean Precious Metals, Viatris, or Biomx?
-
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $2.07
- Day Range
- $1.93–2.07
- 52-Week Range
- $0.52–3.35
- Bid/Ask
- $1.92 / $2.20
- Market Cap
- $70.96 Mil
- Volume/Avg
- 117,782 / 245,965
Key Statistics
- Price/Earnings (Normalized)
- 1.92
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
- Website
- https://www.enterabio.com
Valuation
|
Metric
|
ENTX
|
|---|---|
Price/Earnings (Normalized) | 1.92 |
Price/Book Value | 6.83 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ENTX
Financial Strength
|
Metric
|
ENTX
|
|---|---|
Quick Ratio | 10.10 |
Current Ratio | 10.32 |
Interest Coverage | — |
Quick Ratio
ENTX
Profitability
|
Metric
|
ENTX
|
|---|---|
Return on Assets (Normalized) | −68.35% |
Return on Equity (Normalized) | −81.27% |
Return on Invested Capital (Normalized) | −79.17% |
Return on Assets
ENTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ldphzsgfy | Jlzs | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jhmwhwss | Qxvgw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ckxcsdzps | Lvmbg | $97.8 Bil | |
MRNA
| Moderna Inc | Mjkgkhz | Gfjcs | $38.8 Bil | |
ARGX
| argenx SE ADR | Ghhjhxpwf | Mfzpq | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Yskpksfw | Lbvm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qhxzpykp | Zqxgfw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bszbkhgqy | Wjbxf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ytqgzwdjh | Xjjfrgc | $12.5 Bil | |
INCY
| Incyte Corp | Fgdzlghw | Fmwbc | $11.5 Bil |